secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001108205-24-000071
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q3 net loss narrows to $10.1M; emavusertib shows durable responses in BTKi-progressed PCNSL
--------------------------------------------------------------------------------

- Net loss of $10.1M ($1.70 per share) vs $12.2M ($2.13) in Q3 2023; nine-month net loss $33.8M.
- Revenue $2.9M from Erivedge royalties, essentially flat YoY.
- Cash $31.6M after $10.8M October offering; expects runway into mid-2025.
- Emavusertib in PCNSL: 3 CR + 1 CRu + 2 PR among 10 BTKi-progressed patients; 3 responses >6 months.
- Oral and poster presentations on emavusertib in AML/MDS at ASH in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000071/0001108205-24-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000071/cris-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001108205-24-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer